Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.8B | $41.8B | $48.6B | $154B | $160B | $174B | $181B | $195B | $247B | $275B |
| Revenue growth | — | 4.9% | 16.4% | 215.7% | 4.5% | 8.5% | 3.7% | 8.2% | 26.6% | 11.2% |
| Operating income | $3.09B | $3.94B | $4.16B | $8.08B | $8.15B | $7.94B | $8.45B | $8.54B | $9.42B | $9.20B |
| Operating margin | 7.8% | 9.4% | 8.6% | 5.3% | 5.1% | 4.6% | 4.7% | 4.4% | 3.8% | 3.3% |
| Net income | $1.84B | $2.23B | $2.65B | $5.12B | $8.49B | $5.42B | $6.78B | $5.16B | $3.43B | $5.96B |
| Net margin | 4.6% | 5.3% | 5.4% | 3.3% | 5.3% | 3.1% | 3.8% | 2.6% | 1.4% | 2.2% |
| EPS (diluted) | $7.19 | $8.77 | $10.54 | $13.44 | $22.96 | $15.75 | $21.41 | $17.39 | $12.12 | $22.18 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.03B | $4.09B | $3.77B | $9.48B | $10.3B | $7.19B | $8.66B | $11.8B | $10.4B | $9.60B |
| Capital expenditures | $461M | $471M | $528M | $1.05B | — | — | — | — | — | — |
| Free cash flow | $3.56B | $3.62B | $3.24B | $8.44B | — | — | — | — | — | — |
| Share buybacks | $139M | $2.73B | $342M | $1.99B | $4.04B | $7.74B | $7.61B | $2.28B | $7.03B | $3.62B |
| Dividends paid | — | — | — | $15.0M | $15.0M | $345M | $357M | $368M | $401M | $412M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.19B | $2.97B | $3.85B | $4.62B | $10.2B | $5.08B | $5.92B | $7.82B | $7.55B | $7.68B |
| Total assets | — | $61.8B | $153B | $156B | $155B | $155B | $144B | $153B | $156B | $158B |
| Total liabilities | — | $48.0B | $112B | $110B | $105B | $108B | $99.1B | $106B | $115B | $116B |
| Shareholders' equity | $13.7B | $13.7B | $41.0B | $45.3B | $50.3B | $47.1B | $44.7B | $46.2B | $41.0B | $41.7B |
| Retained earnings | — | $15.8B | $15.1B | $20.2B | $28.6B | $32.6B | $37.9B | $41.7B | $43.5B | $47.9B |
| Shares (wtd avg diluted) | 260M | 255M | 250M | 380M | 368M | 341M | 313M | 297M | 283M | 269M |
Every figure is extracted from Cigna Group’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.